Form 4: Lyell Immunopharma CFO Charles W. Newton Reports Stock and Option Awards

Charles W. Newton, CFO of Lyell Immunopharma, reports the acquisition of stock and option awards, including restricted stock units and performance-based options, as per a recent SEC Form 4 filing.

Summary

• Charles W. Newton, the Chief Financial Officer of Lyell Immunopharma, filed a Form 4 with the SEC.
• The filing reports the acquisition of 112,500 shares of common stock and options to purchase 506,250 shares of common stock.
• These acquisitions include restricted stock units and performance-based options.
• The restricted stock units vest over time, with 12.5% vesting on August 9, 2025, and the remainder vesting quarterly thereafter.
• Similarly, 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares vesting monthly over the following forty-two months.
• The performance-based options are subject to vesting upon the achievement of specified performance criteria.
• Newton directly owns 172,725 shares of common stock following the reported transactions.
• The exercise price for the options is $0.5535.
• The options expire on February 9, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reporting insider transactions. The acquisition of shares and options could be interpreted as a positive sign of confidence, but it's also part of standard compensation practices.

Positives

• The acquisition of stock and options by the CFO could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedules for the restricted stock units and options extend into the future, contingent on continued service and, in some cases, achievement of performance criteria.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing indicates the CFO's ongoing investment in the company.

Comparison to Industry Standards

• Stock and option grants are a common form of compensation for executives in the biotechnology industry.
• Vesting schedules are typically structured to incentivize long-term commitment and performance.
• The specific terms of the grants (e.g., vesting schedule, exercise price) would need to be compared to those of peer companies to assess their competitiveness.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The vesting schedules for the stock and options incentivize the CFO to remain with the company and contribute to its success.

Key Dates